Lurbinectedin (Zepzelca) is an alkylating agent indicated for the maintenance treatment of extensive-stage small cell lung cancer (ES-SCLC) and for the treatment of patients with metastatic small cell lung cancer (SCLC) who have progressed following platinum-based chemotherapy. As an intravenously administered targeted medication, lurbinectedin demonstrates significant efficacy while carrying a certain risk of side effects, among which some severe adverse reactions require close clinical attention.

Side Effects of Lurbinectedin (Zepzelca)

Common Adverse Reactions in Monotherapy

Hematological Toxicity: Leukopenia, lymphopenia, anemia, neutropenia, thrombocytopenia.

Gastrointestinal Reactions: Nausea (37%), vomiting (22%), diarrhea (20%), constipation (31%), decreased appetite (33%).

Systemic Reactions: Fatigue (77%), pyrexia (13%).

Musculoskeletal System: Musculoskeletal pain (33%).

Respiratory System: Dyspnea (31%), cough (20%).

Common Adverse Reactions in Combination Therapy

Hematological Toxicity: Lymphopenia (55%), thrombocytopenia (54%), decreased hemoglobin (51%), neutropenia (36%).

Gastrointestinal Reactions: Nausea (36%), vomiting (14%), diarrhea (15%), constipation (12%).

Systemic Reactions: Fatigue (32%).

Severe Side Effects of Lurbinectedin (Zepzelca)

Myelosuppression

Lurbinectedin can cause severe, even life-threatening myelosuppression, including febrile neutropenia, sepsis, thrombocytopenia, and anemia.

Neutropenia: Incidence of 36%, with 18% being grade 3 or 4.

Thrombocytopenia: Incidence of 54%, with 15% reaching grade 3 or 4.

Decreased Hemoglobin: Incidence of 51%, with 13% being severe.

Hepatotoxicity

Lurbinectedin can induce drug-induced liver injury, which requires special attention.

ALT Elevation: Incidence of 25%, with 3% being grade 3 or 4.

AST Elevation: Incidence of 24%, with 3% being severe.

Precautions for Lurbinectedin (Zepzelca) Administration

Hepatic Function Monitoring

Monitor hepatic function prior to initiating treatment.

Perform regular testing during treatment.

Conduct additional monitoring based on clinical indications.

Muscle Function Monitoring

Regularly monitor creatine phosphokinase (CPK) levels before and during treatment.

Adjust the monitoring frequency as clinically needed.

Recommended Administration Route

Administration via a central venous catheter is recommended to reduce the risk of extravasation.

For peripheral venous administration, a minimum of 250 mL of diluent must be used.

Intravenous infusion time: 60 minutes.

Incompatibilities

Nylon membrane filters are prohibited when diluting with 0.9% Sodium Chloride Injection.

A 0.22-micron polyethersulfone (PES) in-line filter is recommended.